SMT202100699T1 - Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi - Google Patents

Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi

Info

Publication number: SMT202100699T1
Authority: SM; San Marino
Prior art keywords: pyrazols; ylamino; pyrimidin; treatment; neurodegenerative disorders
Prior art date: 2016-06-16

Application number

SM20210699T

Other languages

English (en)

Italian (it)

Inventor

Anthony A Estrada

Jianwen A Feng

Joseph P Lyssikatos

Zachary K Sweeney

Vicente Fidalgo Javier De

Original Assignee

Denali Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-06-16

Filing date

2017-06-15

Publication date

2022-01-10

2017-06-15 Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc

2022-01-10 Publication of SMT202100699T1 publication Critical patent/SMT202100699T1/it

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Hematology (AREA)
Oncology (AREA)
Immunology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Medicinal Preparation (AREA)

SM20210699T 2016-06-16 2017-06-15 Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi SMT202100699T1 (it)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201662350876P	2016-06-16	2016-06-16
US201662417151P	2016-11-03	2016-11-03
US201762476581P	2017-03-24	2017-03-24
US201762510711P	2017-05-24	2017-05-24
EP17733306.9A EP3472153B1 (fr)	2016-06-16	2017-06-15	Pyrimidin-2-ylamino -1h-pyrazols comme inhibiteurs de lrrk2 destinés au traitement de troubles neurodégénératifs
PCT/US2017/037782 WO2017218843A1 (fr)	2016-06-16	2017-06-15	Pyrimidin-2-ylamino -1h-pyrazols comme inhibiteurs de lrrk2 destinés au traitement de troubles neurodégénératifs

Publications (1)

Publication Number	Publication Date
SMT202100699T1 true SMT202100699T1 (it)	2022-01-10

Family

ID=59216078

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM20210699T SMT202100699T1 (it)	2016-06-16	2017-06-15	Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi

Country Status (37)

Country	Link
US (7)	US20170362206A1 (fr)
EP (3)	EP4635570A2 (fr)
JP (1)	JP7004459B2 (fr)
KR (3)	KR102705724B1 (fr)
CN (2)	CN109311857B (fr)
AU (3)	AU2017286653B2 (fr)
CA (1)	CA3025672A1 (fr)
CL (1)	CL2018003597A1 (fr)
CO (1)	CO2018013585A2 (fr)
CR (2)	CR20180592A (fr)
CU (1)	CU24605B1 (fr)
CY (1)	CY1124789T1 (fr)
DK (1)	DK3998261T3 (fr)
DO (3)	DOP2018000285A (fr)
EC (1)	ECSP18092481A (fr)
ES (2)	ES2900368T3 (fr)
HR (1)	HRP20211923T1 (fr)
HU (1)	HUE056678T2 (fr)
IL (3)	IL299415B2 (fr)
JO (1)	JOP20180113B1 (fr)
LT (1)	LT3472153T (fr)
MD (1)	MD3472153T2 (fr)
MX (3)	MX392230B (fr)
PE (2)	PE20240221A1 (fr)
PH (1)	PH12018502427A1 (fr)
PL (1)	PL3472153T3 (fr)
PT (1)	PT3472153T (fr)
RS (1)	RS62868B1 (fr)
SA (2)	SA521430638B1 (fr)
SG (2)	SG11201810579YA (fr)
SI (1)	SI3472153T1 (fr)
SM (1)	SMT202100699T1 (fr)
TN (1)	TN2018000422A1 (fr)
TW (1)	TWI786049B (fr)
UA (1)	UA126231C2 (fr)
WO (1)	WO2017218843A1 (fr)
ZA (1)	ZA201900229B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017156493A1 (fr)	2016-03-11	2017-09-14	Denali Therapeutics Inc.	Composés, compositions et procédés
US11214565B2 (en)	2015-11-20	2022-01-04	Denali Therapeutics Inc.	Compound, compositions, and methods
AU2017286653B2 (en)	2016-06-16	2021-11-04	Denali Therapeutics Inc.	Pyrimidin-2-ylamino-1H-pyrazols as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders
SG11202004733WA (en)	2017-11-21	2020-06-29	Denali Therapeutics Inc	Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production
KR20200100757A (ko)	2017-12-20	2020-08-26	데날리 테라퓨틱스 인크.	피리미디닐-4-아미노피라졸 화합물의 제조를 위한 공정
KR20190131981A (ko) *	2018-05-18	2019-11-27	재단법인 대구경북첨단의료산업진흥재단	외상성 뇌손상 또는 뇌졸중의 예방 또는 치료용 약학적 조성물
AR118641A1 (es) *	2019-04-11	2021-10-20	Denali Therapeutics Inc	Compuestos, composiciones y métodos
MX2021014705A (es) *	2019-05-31	2022-04-06	Denali Therapeutics Inc	Formulacion de liberacion modificada de un compuesto de pirimidinilamino-pirazol y metodos de tratamiento.
EP3769768A1 (fr)	2019-07-23	2021-01-27	Consejo Superior de Investigaciones Cientificas (CSIC)	Composés utiles pour le traitement de la maladie de parkinson
EP4051682A1 (fr) *	2019-10-29	2022-09-07	Biogen MA Inc.	Inhibiteurs spirocycliques d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
BR112022018477A2 (pt)	2020-03-23	2022-11-01	Whan In Pharmaceutical Co Ltd	Composto derivado de pirimidina, composição compreendendo o mesmo, e seus usos na prevenção ou tratamento de doenças neurodegenerativas e câncer
KR102342803B1 (ko)	2020-03-23	2021-12-24	환인제약 주식회사	신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물
DK4225306T3 (da) *	2020-10-07	2025-03-24	Alzprotect	Anvendelse af n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-aminsulfatsalte og solvater heraf til behandling af motorneuronsygdomme og neuromuskulære forbindelseslidelser
CN114426542B (zh) *	2020-10-29	2023-06-30	苏州亚宝药物研发有限公司	取代的二芳基胺化合物及其药物组合物、制备方法和用途
US20240207266A1 (en) *	2021-04-30	2024-06-27	Denali Therapeutics Inc.	Methods for treating and monitoring parkinson's disease
AR127470A1 (es)	2021-10-27	2024-01-31	H Lundbeck As	Inhibidores de lrrk2
CA3250447A1 (fr)	2021-12-15	2025-07-09	Whan In Pharmaceutical Co., Ltd.	Dérivé de pyrimidine macrocyclique, son procédé de préparation, et composition pharmaceutique destinée à la prévention ou au traitement d'une maladie neurodégénérative et contenant ce dérivé en tant que principe actif
CN117624185B (zh) *	2022-08-23	2025-12-05	长春金赛药业有限责任公司	Lrrk2抑制剂化合物、药物组合物及其制备方法和应用
US11958865B1 (en)	2022-09-15	2024-04-16	H. Lundbeck A/S	Leucine-rich repeat kinase 2 (LRRK2) inhibitors
AU2023371948A1 (en)	2022-11-03	2025-05-15	Denali Therapeutics Inc.	Solid and co-crystal forms of a pyrimidine triazole compound
CN115894456A (zh) *	2022-11-13	2023-04-04	药康众拓(江苏)医药科技有限公司	一种氘代吡唑氨基嘧啶类化合物、药物组合物和用途
KR20250102043A (ko)	2022-11-22	2025-07-04	데날리 테라퓨틱스 인크.	피리미딘 아미노피라졸 화합물의 제조 방법 및 중간체
CN115819405A (zh) *	2022-12-20	2023-03-21	沪渝人工智能研究院	嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用
WO2025051214A1 (fr) *	2023-09-07	2025-03-13	上海翊石医药科技有限公司	Composé hétérocyclique aromatique et son procédé de préparation
CN118878521B (zh) *	2024-09-26	2025-02-14	苏州美诺医药科技有限公司	一种lrrk2抑制剂的制备方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1058549A4 (fr)	1998-12-23	2003-11-12	Bristol Myers Squibb Pharma Co	INHIBITEURS DU FACTEUR Xa OU DE LA THROMBINE
WO2003076658A2 (fr)	2002-03-08	2003-09-18	Decode Genetics Ehf.	Gene de predisposition a la maladie de parkinson idiopathique a apparition tardive
US7202257B2 (en)	2003-12-24	2007-04-10	Deciphera Pharmaceuticals, Llc	Anti-inflammatory medicaments
US7144911B2 (en)	2002-12-31	2006-12-05	Deciphera Pharmaceuticals Llc	Anti-inflammatory medicaments
US7371759B2 (en) *	2003-09-25	2008-05-13	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
AR049418A1 (es)	2004-02-27	2006-08-02	Bayer Pharmaceuticals Corp	Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
US8211929B2 (en)	2004-12-30	2012-07-03	Exelixis, Inc.	Pyrimidine derivatives as kinase modulators and method of use
EP1746096A1 (fr)	2005-07-15	2007-01-24	4Sc Ag	Analogues de 2-arylbenzothiazole utiles comme agents anticancereux
US20090247554A1 (en)	2006-03-30	2009-10-01	Takeda San Diego, Inc.	Kinase inhibitors
BRPI0713738A2 (pt)	2006-06-20	2014-06-24	Novartis Ag	Biomarcadores para a progressão de doença alzheimer
WO2008118822A1 (fr)	2007-03-23	2008-10-02	Rigel Pharmaceuticals, Inc.	Compositions et procédés d'inhibition de la voie de jak
AR068072A1 (es)	2007-04-19	2009-11-04	Novartis Ag	Derivados de bencimidazoles, composiciones farmaceuticas y usos
CN101679378A (zh)	2007-05-02	2010-03-24	沃泰克斯药物股份有限公司	用作激酶抑制剂的噻唑和吡唑
CN101687852A (zh)	2007-05-24	2010-03-31	沃泰克斯药物股份有限公司	可用作激酶抑制剂的噻唑类和吡唑类化合物
AU2008296479A1 (en)	2007-08-28	2009-03-12	Dana Farber Cancer Institute	Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
WO2009127642A2 (fr)	2008-04-15	2009-10-22	Cellzome Limited	Utilisation d’inhibiteurs de lrrk2 pour maladies neurodégénératives
AR075713A1 (es)	2009-03-03	2011-04-20	Du Pont	Pirazoles fungicidas
WO2010111406A2 (fr)	2009-03-24	2010-09-30	Myriad Pharmaceuticals, Inc.	Composés et leurs utilisations thérapeutiques
TW201111385A (en)	2009-08-27	2011-04-01	Biocryst Pharm Inc	Heterocyclic compounds as janus kinase inhibitors
CA2780892C (fr)	2009-11-13	2017-02-14	Genosco	Inhibiteurs de kinases
GB201008134D0 (en)	2010-05-14	2010-06-30	Medical Res Council Technology	Compounds
AU2011260323A1 (en)	2010-06-04	2012-11-15	F. Hoffmann-La Roche Ag	Aminopyrimidine derivatives as LRRK2 modulators
WO2011156698A2 (fr)	2010-06-11	2011-12-15	Abbott Laboratories	Nouveaux composés de pyrazolo[3,4-d]pyrimidine
US9233977B2 (en)	2010-10-29	2016-01-12	Merck Sharp & Dohme Corp.	Leucine-rich repeat kinase enzyme activity
DK2638031T3 (en)	2010-11-10	2017-12-11	Genentech Inc	PYRAZOLAMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS
JP2014504362A (ja)	2010-11-30	2014-02-20	ジェネンテック，インコーポレイテッド	Ｌｒｒｋ２のためのアッセイ及びバイオマーカー
EP2720719A4 (fr)	2011-06-15	2015-12-09	Glaxosmithkline Ip No 2 Ltd	Procédé de sélection d'indications thérapeutiques
CN103781780B (zh)	2011-07-28	2015-11-25	赛尔佐姆有限公司	作为jak抑制剂的杂环基嘧啶类似物
PH12014500638A1 (en)	2011-09-22	2017-08-09	Pfizer	Pyrrolopyrimidine and purine derivatives
WO2013079493A1 (fr)	2011-11-29	2013-06-06	F. Hoffmann-La Roche Ag	Dérivés aminopyridines en tant que modulateurs de lrrk2
CA2850594C (fr)	2011-11-29	2020-03-10	F. Hoffmann-La Roche Ag	Derives aminopyrimidiniques utilises comme modulateurs de lrrk2
AR089182A1 (es)	2011-11-29	2014-08-06	Hoffmann La Roche	Derivados de aminopirimidina como moduladores de lrrk2
HRP20161396T1 (hr)	2011-11-29	2016-12-02	F. Hoffmann - La Roche Ag	Derivati 2-(fenil ili pirid-3-il)aminopirimidina kao modulatori lrrk2-kinaze za liječenje parkinsonove bolesti
RU2650641C2 (ru)	2011-11-30	2018-04-16	Дженентек, Инк.	Фтор-18 и углерод-11 меченые радиолиганды для томографии с позитронной эмиссией (рет), визуализирующей lrrk2
WO2013126283A1 (fr)	2012-02-20	2013-08-29	E. I. Du Pont De Nemours And Company	Pyrazoles fongicides
SI2820009T1 (en)	2012-03-01	2018-05-31	Array Biopharma, Inc.	Serine / Threonine kinase inhibitors
BR112014027117B1 (pt) *	2012-05-03	2022-09-06	Genentech, Inc	Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
MX363118B (es)	2012-05-03	2019-03-11	Genentech Inc	Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
WO2017156493A1 (fr)	2016-03-11	2017-09-14	Denali Therapeutics Inc.	Composés, compositions et procédés
US9624180B2 (en)	2013-01-25	2017-04-18	Bristol-Myers Squibb Company	Squaric derivatives for the treatment of hepatitis C
WO2014130241A1 (fr)	2013-02-20	2014-08-28	E. I. Du Pont De Nemours And Company	Pyrazoles fongicides
CA2903901A1 (fr)	2013-03-05	2014-09-12	Merck Patent Gmbh	Derives de 9-(aryl ou heteroaryl)-2-(pyrazolyl, pyrrolidinyl ou cyclopentyl)aminopurine utilises en tant qu'agents anticancereux
EP3388436B1 (fr)	2013-03-15	2020-08-12	Dana-Farber Cancer Institute, Inc.	Composés pyrimido-diazépinone et procédés de traitement de maladies
US20160024071A1 (en)	2013-03-15	2016-01-28	Elan Pharmaceuticals, Llc	Inhibitors of lrrk2 kinase activity
TW201533043A (zh) *	2013-04-18	2015-09-01	Lundbeck & Co As H	作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
WO2014181287A1 (fr)	2013-05-09	2014-11-13	Piramal Enterprises Limited	Composés hétérocyclyliques et leurs utilisations
DK2994465T3 (en)	2013-05-10	2018-10-08	Karus Therapeutics Ltd	HISTONDEACETYLASE INHIBITORS UNKNOWN
SG11201605342UA (en)	2014-01-29	2016-08-30	Glaxosmithkline Ip Dev Ltd	Compounds
US9580430B2 (en)	2014-02-28	2017-02-28	The Regents Of The University Of Michigan	9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
JP6517318B2 (ja)	2014-03-28	2019-05-22	キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒＳｃｉｅｎｃｅｓ，Ｌｌｃ	置換されたヘテロアリール化合物および使用方法
JP6684780B2 (ja)	2014-08-25	2020-04-22	ソークインスティテュートフォーバイオロジカルスタディーズ	新規ｕｌｋ１阻害剤およびそれを使用する方法
CN105461694B (zh)	2014-09-27	2019-05-24	广东东阳光药业有限公司	取代的杂芳基化合物及其组合物和用途
WO2016090285A1 (fr)	2014-12-05	2016-06-09	Array Biopharma Inc.	Pyrazolo[1,5-a] pyrazines substituées en 4,6 en tant qu'inhibiteurs de la janus kinase
WO2016149311A1 (fr)	2015-03-19	2016-09-22	E I Du Pont De Nemours And Company	Pyrazoles fongicides
JP2018135268A (ja)	2015-06-05	2018-08-30	大日本住友製薬株式会社	新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩
CA2986441A1 (fr)	2015-06-12	2016-12-15	Dana-Farber Cancer Institute, Inc.	Therapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
KR102161364B1 (ko)	2015-09-14	2020-09-29	화이자 인코포레이티드	LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
EP3377629B1 (fr)	2015-11-18	2023-07-05	Rosalind Franklin University of Medicine and Science	Composés antisens ciblant une kinase 2 à répétition riche en leucine (lrrk2) pour le traitement de la maladie de parkinson
US11214565B2 (en)	2015-11-20	2022-01-04	Denali Therapeutics Inc.	Compound, compositions, and methods
TW201720828A (zh)	2015-11-23	2017-06-16	赫孚孟拉羅股份公司	治療性化合物及組合物以及其使用方法
WO2017100703A1 (fr)	2015-12-10	2017-06-15	Colin Combs	Analogues ems d'inhibiteurs de lyn-src-tyrosine kinase
US10023579B2 (en)	2015-12-16	2018-07-17	Southern Research Institute	Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
TWI781920B (zh) *	2016-02-05	2022-11-01	美商戴納立製藥公司	化合物、組合物及方法
AU2017286653B2 (en)	2016-06-16	2021-11-04	Denali Therapeutics Inc.	Pyrimidin-2-ylamino-1H-pyrazols as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders
US20200157081A1 (en)	2017-05-24	2020-05-21	Denali Therapeutics Inc.	Compounds, compositions and methods

2017
- 2017-06-15 AU AU2017286653A patent/AU2017286653B2/en active Active
- 2017-06-15 IL IL299415A patent/IL299415B2/en unknown
- 2017-06-15 PE PE2023001478A patent/PE20240221A1/es unknown
- 2017-06-15 ES ES17733306T patent/ES2900368T3/es active Active
- 2017-06-15 JP JP2018565694A patent/JP7004459B2/ja active Active
- 2017-06-15 PT PT177333069T patent/PT3472153T/pt unknown
- 2017-06-15 UA UAA201812165A patent/UA126231C2/uk unknown
- 2017-06-15 SG SG11201810579YA patent/SG11201810579YA/en unknown
- 2017-06-15 HU HUE17733306A patent/HUE056678T2/hu unknown
- 2017-06-15 KR KR1020237022665A patent/KR102705724B1/ko active Active
- 2017-06-15 ES ES21198102T patent/ES3036953T3/es active Active
- 2017-06-15 PE PE2018003221A patent/PE20190395A1/es unknown
- 2017-06-15 SM SM20210699T patent/SMT202100699T1/it unknown
- 2017-06-15 LT LTEPPCT/US2017/037782T patent/LT3472153T/lt unknown
- 2017-06-15 SI SI201731005T patent/SI3472153T1/sl unknown
- 2017-06-15 CU CU2018000152A patent/CU24605B1/es unknown
- 2017-06-15 TN TNP/2018/000422A patent/TN2018000422A1/en unknown
- 2017-06-15 IL IL299412A patent/IL299412B2/en unknown
- 2017-06-15 US US15/624,566 patent/US20170362206A1/en not_active Abandoned
- 2017-06-15 RS RS20211513A patent/RS62868B1/sr unknown
- 2017-06-15 HR HRP20211923TT patent/HRP20211923T1/hr unknown
- 2017-06-15 EP EP25174508.9A patent/EP4635570A2/fr active Pending
- 2017-06-15 EP EP17733306.9A patent/EP3472153B1/fr active Active
- 2017-06-15 CR CR20180592A patent/CR20180592A/es unknown
- 2017-06-15 MX MX2018015630A patent/MX392230B/es unknown
- 2017-06-15 SG SG10201912632YA patent/SG10201912632YA/en unknown
- 2017-06-15 WO PCT/US2017/037782 patent/WO2017218843A1/fr not_active Ceased
- 2017-06-15 KR KR1020197000749A patent/KR102553188B1/ko active Active
- 2017-06-15 JO JOP/2018/0113A patent/JOP20180113B1/ar active
- 2017-06-15 EP EP21198102.2A patent/EP3998261B1/fr active Active
- 2017-06-15 CN CN201780036925.3A patent/CN109311857B/zh active Active
- 2017-06-15 IL IL263484A patent/IL263484B2/en unknown
- 2017-06-15 KR KR1020247029993A patent/KR102843750B1/ko active Active
- 2017-06-15 MD MDE20190504T patent/MD3472153T2/ro unknown
- 2017-06-15 DK DK21198102.2T patent/DK3998261T3/da active
- 2017-06-15 CN CN202111282850.1A patent/CN114315819A/zh active Pending
- 2017-06-15 CA CA3025672A patent/CA3025672A1/fr active Pending
- 2017-06-15 PL PL17733306T patent/PL3472153T3/pl unknown
- 2017-06-15 CR CR20220182A patent/CR20220182A/es unknown
- 2017-06-16 TW TW106120263A patent/TWI786049B/zh active
- 2017-10-25 US US15/793,882 patent/US9932325B2/en active Active
2018
- 2018-03-21 US US15/927,920 patent/US10590114B2/en active Active
- 2018-11-19 PH PH12018502427A patent/PH12018502427A1/en unknown
- 2018-12-13 MX MX2022005610A patent/MX2022005610A/es unknown
- 2018-12-13 DO DO2018000285A patent/DOP2018000285A/es unknown
- 2018-12-13 SA SA521430638A patent/SA521430638B1/ar unknown
- 2018-12-13 MX MX2021010304A patent/MX2021010304A/es unknown
- 2018-12-13 SA SA518400660A patent/SA518400660B1/ar unknown
- 2018-12-14 EC ECSENADI201892481A patent/ECSP18092481A/es unknown
- 2018-12-14 CO CONC2018/0013585A patent/CO2018013585A2/es unknown
- 2018-12-14 CL CL2018003597A patent/CL2018003597A1/es unknown
2019
- 2019-01-14 ZA ZA2019/00229A patent/ZA201900229B/en unknown
2020
- 2020-03-13 US US16/818,745 patent/US11111235B2/en active Active
2021
- 2021-08-13 US US17/401,833 patent/US11591316B2/en active Active
- 2021-12-14 CY CY20211101098T patent/CY1124789T1/el unknown
2022
- 2022-04-08 AU AU2022202372A patent/AU2022202372B2/en active Active
- 2022-04-25 DO DO2022000088A patent/DOP2022000088A/es unknown
2023
- 2023-01-19 US US18/099,082 patent/US11834439B2/en active Active
- 2023-04-17 DO DO2023000077A patent/DOP2023000077A/es unknown
2024
- 2024-06-14 US US18/744,133 patent/US20250034119A1/en active Pending
- 2024-07-03 AU AU2024204621A patent/AU2024204621A1/en active Pending

Also Published As

Publication number	Publication date
CU20180152A7 (es)	2019-09-04
HRP20211923T1 (hr)	2022-03-04
AU2022202372B2 (en)	2024-04-04
IL263484B1 (en)	2023-10-01
KR20190018676A (ko)	2019-02-25
ES3036953T3 (en)	2025-09-26
PE20240221A1 (es)	2024-02-16
US20210002260A1 (en)	2021-01-07
SA518400660B1 (ar)	2023-06-04
CN114315819A (zh)	2022-04-12
CR20180592A (es)	2019-03-05
IL299412A (en)	2023-02-01
AU2022202372A1 (en)	2022-04-28
WO2017218843A1 (fr)	2017-12-21
JP7004459B2 (ja)	2022-02-10
ES2900368T3 (es)	2022-03-16
DK3998261T3 (da)	2025-08-18
EP4635570A2 (fr)	2025-10-22
JOP20180113B1 (ar)	2022-03-14
AU2017286653A1 (en)	2018-12-20
AU2017286653B2 (en)	2021-11-04
IL263484A (en)	2019-01-31
PE20190395A1 (es)	2019-03-13
US11834439B2 (en)	2023-12-05
ECSP18092481A (es)	2018-12-31
DOP2022000088A (es)	2022-06-15
DOP2018000285A (es)	2019-01-15
EP3472153A1 (fr)	2019-04-24
LT3472153T (lt)	2021-12-27
US20250034119A1 (en)	2025-01-30
TN2018000422A1 (en)	2020-06-15
PT3472153T (pt)	2021-12-31
IL299412B2 (en)	2025-05-01
CU24605B1 (es)	2022-06-06
SA521430638B1 (ar)	2023-07-12
CO2018013585A2 (es)	2019-01-18
KR20240137707A (ko)	2024-09-20
US20180208582A1 (en)	2018-07-26
IL299412B1 (en)	2025-01-01
IL299415B1 (en)	2025-05-01
BR112018075569A2 (pt)	2019-03-19
KR20230107407A (ko)	2023-07-14
PH12018502427A1 (en)	2019-09-30
CL2018003597A1 (es)	2019-02-15
ZA201900229B (en)	2022-10-26
EP3998261B1 (fr)	2025-05-07
US20230227436A1 (en)	2023-07-20
US20170362206A1 (en)	2017-12-21
CY1124789T1 (el)	2022-11-25
CN109311857A (zh)	2019-02-05
JOP20180113A1 (ar)	2019-01-30
US20180051009A1 (en)	2018-02-22
MX392230B (es)	2025-03-21
SI3472153T1 (sl)	2022-01-31
EP3472153B1 (fr)	2021-09-22
CR20220182A (es)	2022-06-15
JP2019521984A (ja)	2019-08-08
CA3025672A1 (fr)	2017-12-21
MD3472153T2 (ro)	2022-03-31
SG11201810579YA (en)	2018-12-28
UA126231C2 (uk)	2022-09-07
US11111235B2 (en)	2021-09-07
AU2024204621A1 (en)	2024-07-18
RS62868B1 (sr)	2022-02-28
NZ748936A (en)	2024-12-20
MX2021010304A (es)	2021-10-13
CN109311857B (zh)	2021-11-12
HUE056678T2 (hu)	2022-02-28
US9932325B2 (en)	2018-04-03
IL299415B2 (en)	2025-09-01
IL263484B2 (en)	2024-02-01
US20220135546A1 (en)	2022-05-05
DOP2023000077A (es)	2023-05-31
EP3998261A1 (fr)	2022-05-18
KR102843750B1 (ko)	2025-08-07
TW201835069A (zh)	2018-10-01
US11591316B2 (en)	2023-02-28
MX2018015630A (es)	2019-04-11
SG10201912632YA (en)	2020-02-27
IL299415A (en)	2023-02-01
KR102553188B1 (ko)	2023-07-11
KR102705724B1 (ko)	2024-09-12
US10590114B2 (en)	2020-03-17
MX2022005610A (es)	2022-06-23
PL3472153T3 (pl)	2022-02-07
TWI786049B (zh)	2022-12-11

Publication	Publication Date	Title
SG10201912632YA (en)	2020-02-27	Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
IL261721A (en)	2018-10-31	Combinations of lsd1 inhibitors for use in the treatment of solid tumors
SG11201607705XA (en)	2016-10-28	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
IL246833A0 (en)	2016-08-31	New salts and their pharmaceutical preparations for the treatment of inflammatory disorders
PL3380471T3 (pl)	2021-12-20	Tetrahydro-8h-pirydo[1,2-a]pirazyn-8-ony jako inhibitory comt do leczenia chorób i zaburzeń neurodegeneracyjnych
IL247589A0 (en)	2016-11-30	Dihydropyridine mgat2 inhibitors for use in the treatment of metabolic disorders
HUE039750T2 (hu)	2019-02-28	Hidroxi-buspiron mozgászavarok kezelésére
SG11201608397UA (en)	2016-11-29	Glyt1 inhibitors for use in the treatment of hematological disorders
SG11201708181RA (en)	2017-11-29	Methods for the treatment of inflammatory disorders
IL263862A (en)	2019-01-31	Mitochondrial inhibitors for the treatment of proliferation disorders
PL3377089T3 (pl)	2020-06-29	Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego
EP3131635A4 (fr)	2017-10-11	Compositions et méthodes de traitement ou de prévention de la tuberculose
IL259383A (en)	2018-07-31	A compound for use in the prevention and treatment of neurodegenerative diseases
EP3200795A4 (fr)	2018-06-20	Utilisation d'agents pour le traitement de troubles lipidiques
ZA201806894B (en)	2023-03-29	(+)-azasetron for use in the treatment of ear disorders
HK40007576A (en)	2020-06-05	Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
PT3442537T (pt)	2024-04-11	(+)-azasetrom para utilização no tratamento de doenças do ouvido
GB201521543D0 (en)	2016-01-20	Methods for the treatment of inflammatory disorders
GB201513993D0 (en)	2015-09-23	Methods for the treatment of inflammatory disorders
GB201513345D0 (en)	2015-09-09	Methods for the treatment of Inflammatory disorders
GB201507113D0 (en)	2015-06-10	Methods for the treatment of inflammatory disorders
GB201506419D0 (en)	2015-05-27	Methods for the treatment of inflammatory disorders
GB201506229D0 (en)	2015-05-27	Methods For the Treatment Of Inflammatory Disorders
AU2014901398A0 (en)	2014-05-08	Compositions and methods for the treatment or prevention of neurodegenerative disorders